Chime Financial, Inc. Class A Common Stock
CHYM
$20.79
-5.84%
Chime Financial, Inc. is a financial technology company that provides digital banking services, including spending accounts, savings products, and credit-building tools, through its proprietary platform in partnership with third-party banks, operating within the Financial Services sector and specifically the Regional Banks industry. The company is a prominent disruptor in the neobanking space, distinct for its mobile-first, fee-avoidant model targeting consumers underserved by traditional banks. The current investor narrative is heavily focused on the company's path to sustainable profitability following its recent IPO, with recent financial trends showing robust revenue growth but persistent net losses, driving debate around its ability to scale its user base while improving unit economics and navigating an increasingly competitive digital finance landscape.…
CHYM
Chime Financial, Inc. Class A Common Stock
$20.79
CHYM 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Chime Financial, Inc. Class A Common Stock's 12-month outlook, with a consensus price target around $27.03 and implied upside of +30.0% versus the current price.
Average Target
$27.03
11 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
11
covering this stock
Price Range
$17 - $27
Analyst target range
Analyst coverage for CHYM is limited, with data indicating only 4 analysts providing estimates. The consensus sentiment appears mixed but leans cautiously optimistic, as evidenced by recent institutional ratings which include actions like 'Buy' from Goldman Sachs and 'Outperform' from Evercore ISI, alongside 'Neutral' from UBS. The average target price or explicit buy/hold/sell distribution is not provided in the data, so the implied upside to a consensus target cannot be calculated. The available data shows analysts are actively monitoring the stock, with several reiterations of ratings following quarterly results. The analyst estimates provide a range for future performance, with estimated EPS for the next period between $1.105 and $1.163, and estimated revenue between $4.04 billion and $4.20 billion. The relatively tight range on EPS estimates suggests some consensus on near-term profitability projections. The pattern of institutional ratings shows no recent downgrades, with the latest actions in February 2026 being reiterations. However, the limited number of covering analysts (4) is a notable point; sparse coverage is typical for a recently public company and can lead to higher volatility and less efficient price discovery as the investment story is still being established in the institutional marketplace.
Bulls vs Bears: CHYM Investment Factors
The evidence presents a stark dichotomy between CHYM's strong top-line growth, superior gross margins, and cash flow potential against its persistent losses, premium valuation, and terrible capital efficiency. Currently, the bear side holds stronger evidence, as the market has rightfully punished the stock for its failure to translate rapid revenue growth into profits, resulting in a -35% one-year return. The single most important tension in the investment debate is whether the company can achieve the operating expense leverage necessary to bridge its 85.9% gross margin down to a positive net margin before growth decelerates or investor patience runs out. The recent 28% monthly rally suggests hope, but it is fragile and built on future promises rather than current fundamentals.
Bullish
- Strong Revenue Growth Trajectory: Q4 2025 revenue grew 25.5% YoY to $596.4M, demonstrating robust demand for its digital banking services. The forward PS ratio of ~14.4, based on analyst revenue estimates of $4.14B, suggests the market is pricing in continued high growth.
- Exceptional Gross Margin Profile: Gross margins are exceptionally high at 85.9% (TTM) and 81.2% (Q4), a hallmark of its asset-light fintech model. This provides a strong foundation for future profitability if operating expense leverage can be achieved.
- Positive Free Cash Flow Generation: The company generated positive TTM free cash flow of $32.1M and $17.6M in Q4 2025. This indicates the core business can fund some operations internally, reducing near-term liquidity risk despite net losses.
- Analyst Projections for Profitability: Analysts project a significant turnaround, with estimated EPS for the next period between $1.11 and $1.16. This tight range suggests consensus on a near-term path to profitability, a key catalyst for the stock.
Bearish
- Persistent and Deep Net Losses: The company reported a Q4 2025 net loss of -$44.8M with a trailing EPS of -$0.017. Operating margins of -47.6% show high expenses are overwhelming strong gross profits, raising doubts about the path to sustainable earnings.
- Extremely High Valuation Multiples: The trailing PS ratio of 27.2 is extremely high for a financial services company. This premium valuation is vulnerable to compression if revenue growth decelerates or profitability timelines are pushed out.
- Severe Long-Term Underperformance: The stock is down 35% over the past year, underperforming the SPY by nearly 70 percentage points, with a maximum drawdown of -54.2%. This reflects sustained investor skepticism about its business model and competitive position.
- Abysmal Return on Capital: Return metrics are deeply negative, with an ROA of -21.9% and an ROE of -72.1%. This indicates severe inefficiency in generating profits from its invested capital, a fundamental challenge for value creation.
CHYM Technical Analysis
The stock is in a pronounced downtrend over the past year, with a 1-year price change of -35.004%, significantly underperforming the SPY's 34.9% gain. Currently trading at $24.12, the price sits at approximately 54% of its 52-week range ($16.17 to $44.94), indicating it is positioned closer to its lows than its highs, which may suggest a potential value opportunity but also reflects sustained negative momentum and investor skepticism. The stock has experienced a maximum drawdown of -54.22% over the period, underscoring the severity of the sell-off and the high risk profile for investors who entered near the peak. Recent short-term momentum shows a sharp but potentially fragile recovery, with a 1-month price surge of 28.0935% vastly outperforming the SPY's 7.36% gain, yet this contrasts starkly with the negative 3-month change of -7.4799%. This divergence suggests the recent rally may be a technical rebound or mean reversion within a broader downtrend rather than a confirmed trend reversal; the stock's relative strength over one month is a strong 20.7335, but its 1-year relative strength is deeply negative at -69.904, highlighting the conflicting signals between very recent buying and longer-term bearish sentiment. Key technical levels are clearly defined, with immediate support at the 52-week low of $16.17 and major resistance at the 52-week high of $44.94. A sustained breakout above the recent high near $28 would be necessary to signal a more durable recovery, while a breakdown below the $16 support could trigger another leg down. The stock exhibits high volatility, as evidenced by its dramatic price swings in the provided 180-day data, which is typical for a recently listed growth-oriented fintech; investors must account for this elevated risk in position sizing.
Beta
—
—
Max Drawdown
-54.2%
Largest decline past year
52-Week Range
$16-$45
Price range past year
Annual Return
-44.0%
Cumulative gain past year
| Period | CHYM Return | S&P 500 |
|---|---|---|
| 1m | +8.1% | +10.4% |
| 3m | -4.3% | +5.5% |
| 6m | +14.9% | +8.0% |
| 1y | -44.0% | +28.4% |
| ytd | -21.3% | +6.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CHYM Fundamental Analysis
Revenue growth remains strong but has shown volatility quarter-to-quarter; the most recent Q4 2025 revenue was $596.36 million, representing a solid 25.49% year-over-year growth. However, examining the sequential trend from Q1 2025 ($518.74M) to Q4 2025 ($596.36M) shows growth, but the trajectory was disrupted by a significant net loss in Q2. The single reported revenue segment, 'Payments Revenue' of $771.31 million, suggests the core business is driving top-line expansion, but the investment case hinges on translating this growth into profitability. The company is not consistently profitable, with a net income of -$44.78 million in Q4 2025 and a trailing EPS of -$0.017. Gross margins are exceptionally high at 85.87% (valuation data) and 81.2% (Q4 quarterly), which is a positive hallmark of its asset-light fintech model. However, operating and net margins are deeply negative at -47.56% and -46.18% respectively, indicating that massive operating expenses (SGA of $272.9M in Q4) are overwhelming the strong gross profit. The trend from Q1 2025 (net income of $12.94M) to subsequent quarters of significant losses shows a concerning move away from profitability, largely due to elevated sales, marketing, and R&D spending. The balance sheet shows moderate leverage with a debt-to-equity ratio of 0.096, indicating a primarily equity-financed structure. Liquidity appears strong with a current ratio of 4.53. Critically, the company generated positive free cash flow of $32.11 million on a TTM basis and $17.57 million in Q4 2025, suggesting it can fund some operations internally. However, returns are deeply negative, with an ROA of -21.9% and an ROE of -72.05%, reflecting severe inefficiency in generating profits from its asset and equity base. The financial health is a mix of a strong liquidity position and a problematic path to earning an adequate return on capital.
Quarterly Revenue
$596358000.0B
2025-12
Revenue YoY Growth
+0.25%
YoY Comparison
Gross Margin
+0.81%
Latest Quarter
Free Cash Flow
$32106000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CHYM Overvalued?
Given the company's negative net income and EPS, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 27.2, while the forward-looking metric is implied by the market cap and analyst revenue estimates; with a market cap of $59.47 billion and estimated revenue of $4.14 billion, the forward PS is approximately 14.4, indicating the market is pricing in significant revenue growth to justify the current valuation. Compared to industry averages, direct peer data is not provided in the valuation data set, making a precise sector comparison impossible. However, a PS ratio of 27.2 is extremely high for a financial services company, even a growth-oriented fintech, suggesting the market is awarding a substantial premium for anticipated future scale and market disruption. This premium is predicated on the company's high gross margins and rapid revenue growth, but it remains vulnerable to any deceleration in that growth or failure to improve profitability. Historically, the stock's own PS ratio has fluctuated dramatically, from 15.86 at the end of Q4 2025 to as high as 39.59 at the end of 2023. The current PS of 27.2 sits above the recent Q4 2025 level but below the highs seen in 2023 and early 2024. This positioning in the mid-to-upper range of its own historical band suggests the market's expectations, while lowered from peak optimism, still incorporate a significant growth premium. A re-rating towards lower historical multiples would pose a substantial downside risk if execution falters.
PE
-58.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -172x~8782x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-60.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary risk is the company's inability to achieve profitability despite high gross margins. Operating expenses, particularly SGA at $272.9M in Q4 2025, are consuming gross profit, leading to net margins of -46.2%. The volatile earnings trend—from a $12.9M profit in Q1 2025 to a $44.8M loss in Q4—demonstrates unreliable execution. While free cash flow is positive ($32.1M TTM), negative ROE of -72.1% indicates the business is destroying shareholder value at its current scale and cost structure. Revenue concentration in 'Payments Revenue' also poses a product risk.
Market & Competitive Risks: The stock carries extreme valuation compression risk, trading at a trailing PS of 27.2. This multiple is predicated on flawless execution of high growth; any stumble could trigger a severe de-rating towards historical lows (PS of 15.86 at end of Q4 2025). As a recent IPO with only 4 covering analysts, the stock suffers from low institutional sponsorship and high volatility, exacerbating downside moves. The competitive neobanking landscape is intense, requiring continuous high marketing spend (Selling & Marketing was $164.2M in Q4) to acquire and retain users, pressuring margins.
Worst-Case Scenario: The worst-case involves a combination of revenue growth deceleration below 20% and continued operating margin deterioration, leading to sustained net losses. This would trigger multiple compression as growth investors exit, analyst downgrades, and a loss of access to cheap capital. The realistic downside could see the stock re-test and break its 52-week low of $16.17, representing a potential loss of approximately -33% from the current price of $24.12. A drawdown mirroring the past year's maximum of -54% would imply a price near $11, though that scenario would require a complete loss of investor confidence in the business model.

